New developments in pancreatic cancer

Current Gastroenterology Reports

Volumn 13, Issue 2, 2011, Pages 131-139

  Greer, Julia B ^a   Brand, Randall E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

ABO blood group; Alcohol; Body mass index (BMI); CA 19 9; Cigarette smoking; Diabetes mellitus; Family history; Folate; Gene; Gene expression; Genome wide association study (GWAS); Obesity; PALB2; Pancreatic adenocarcinoma; Signaling pathways; Vitamin D

Indexed keywords

FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GEMCITABINE; PROTEIN PALB2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VITAMIN D;

ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BLOOD GROUP ABO SYSTEM; BODY MASS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CIGARETTE SMOKING; DRUG RESPONSE; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LIFESTYLE; MEDICAL HISTORY; OBESITY; PANCREAS CANCER; PHYSICAL ACTIVITY; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VITAMIN DEFICIENCY;

ADENOCARCINOMA; ADIPOSITY; ALCOHOL DRINKING; BLOOD GROUP ANTIGENS; BODY MASS INDEX; CA-19-9 ANTIGEN; DIET; FOLIC ACID; HEREDITY; HUMANS; MUTATION; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEINS; VITAMIN D;

EID: 79955817730     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-011-0175-y     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 2009, 59:225-49.
2. Brand RE, Lerch MM, Rubinstein WS, et al.: Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007, 56:1460-9. (Pubitemid 47517845)
3. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-6. This landmark study used state-of-the-art DNA sequencing of 20, 735 genes in 24 pancreatic cancers, as well as both gene expression and gene copy number analysis, to identify 12 cellular signaling pathways and processes that had at least one genetic alteration in at least 70% of the tumors. The six specific pathways with alterations of at least one gene in all 24 pancreatic cancers were KRAS signaling, apoptosis, Wnt/Notch signaling, transforming growth factor-β signaling, Hedgehog signaling, and regulation of G1/S phase transition. The study provides compelling evidence that researchers should rethink the candidate gene approach in studying carcinogenesis.
4. Petersen GM, Amundadottir L, Fuchs CS, et al.: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 2010, 42:224-8.
5. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al.: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics 2009, 41:986-90.
6. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al.: Past medical history and pancreatic cancer risk: Results from a multicenter case-control study. Annals of Epidemiology 2010, 20:92-8.
7. Anderson LN, Cotterchio M, Gallinger S, et al.: Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes & Control 2009, 20:825-34.
8. Bao Y, Spiegelman D, Li R, et al.: History of peptic ulcer disease and pancreatic cancer risk in men. Gastroenterology 2010, 138:541-9.
9. Greer JB, Lynch HT, Brand RE.: Hereditary pancreatic cancer: a clinical perspective. Best Practice & Research in Clinical Gastroenterology 2009, 23:159-70.
10. Klein AP, Brune KA, Petersen GM, et al.: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Research 2004, 64:2634-8. (Pubitemid 38523922)
11. Brune KA, Lau B, Palmisano E, et al.: Importance of age of onset in pancreatic cancer kindreds. Journal of the National Cancer Institute 2010, 102:119-26.
12. Jacobs EJ, Rodriguez C, Newton CC, et al.: Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes & Control 2009, 20:1261-9.
13. Risch HA, Yu H, Lu L, et al.: ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. Journal of the National Cancer Institute 2010, 102:502-5.
14. Hannan LM, Jacobs EJ, Thun MJ, et al.: The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:3362-7.
15. Rahman N, Seal S, Thompson D, et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics 2007, 39:165-7. (Pubitemid 46184346)
16. Sy SM, Huen MS, Chen J, et al.: PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7155-60.
17. Jones S, Hruban RH, Kamiyama M, et al.: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
18. Slater EP, Langer P, Niemczyk E, et al.: PALB2 Mutations in European Familial Pancreatic Cancer Families. Clinical Genetics Published online April 2010.
19. Wolpin BM, Chan AT, Hartge P, et al.: ABO blood group and the risk of pancreatic cancer. Journal of the National Cancer Institute 2009, 101:424-31.
20. Wolpin BM, Kraft P, Gross M, et al.: Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Research 2010, 70:1015-23. Building on their previous work demonstrating an association between blood group and the risk of pancreatic cancer, the authors evaluated blood group alleles and found that AA, AO, BB, and BO genotypes carried significantly elevated risks of pancreatic cancer compared with the OO genotype.
21. Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews 2004, Cancer. 4:579-91. (Pubitemid 39025053)
22. Ogden CL, Carroll MD, Flegal KM: High body mass index for age among US children and adolescents, 2003-2006. JAMA 2008, 299:2401-5.
23. Arslan AA, Helzlsouer KJ, Kooperberg C, et al.: Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Archives of Internal Medicine 2010, 170:791-802. This was an amply-powered case-control PanScan study which reinforced previous findings that elevated BMI is associated with pancreatic cancer in both men and women. BMI was evaluated between ages 37 and 94 years, and overweight or obese individuals were diagnosed a mean of 4 months earlier than were normalweight individuals.Furthermore, abdominal obesity (waist-to-hip ratio) was a risk factor for pancreatic cancer among women.
24. Greer JB, Whitcomb DC.: Inflammation and pancreatic cancer: an evidence-based review. Current Opinion in Pharmacology 2009, 9:411-8.
25. Giovannucci E, Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132:2208-25. (Pubitemid 46693749)
26. Giovannucci E: Epidemiologic studies of folate and colorectal neoplasia: a review. Journal of Nutrition 2002, 132:2350S-5S.
27. Oaks BM, Dodd KW, Meinhold CL, et al.: Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. American Journal of Clinical Nutrition 2010, 91:449-55.
28. Gong Z, Holly EA, Bracci PM, et al.: Intake of folate, vitamins B6, B12 and methionine and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes & Control 2009, 20:1317-25.
29. Parker-Pope T: Vitamin D, miracle drug: is it science, or just talk? . New York Times, Science Section 2010, February 1:D1.
30. Giovannucci E: The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes & Control 2005, 16:83-95.
31. Garland CF, Garland FC, Gorham ED, et al.: The role of vitamin D in cancer prevention. American Journal of Public Health 2006, 96:252-61.
32. Bao Y, Ng K, Wolpin BM, et al.: Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. British Journal of Cancer 2010, 102:1422-7.
33. Brand RE, Greer JB, Zolotarevsky E, et al.: Pancreatic cancer patients who smoke and drink are diagnosed at younger ages. Clinical Gastroenterology & Hepatology 2009, 7:1007-12.
34. Talamini R, Polesel J, Gallus S, et al.: Tobacco smoking, alcohol consumption and pancreatic cancer risk: a case-control study in Italy. European Journal of Cancer 2010, 46:370-6.
35. Jiao L, Mitrou PN, Reedy J, et al.: A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Archives of Internal Medicine 2009, 169:764-70.
36. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. Journal of Gastrointestinal Surgery 2000, 4:567-79.
37. Pawlik TM, Gleisner AL, Cameron JL, et al.: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141:610-8. (Pubitemid 46616937)
38. Forsmark CE, Lambiase L, Vogel SB: Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994, 9:731-4. (Pubitemid 24317825)
39. Barton JG, Bois JP, Sarr MG, et al.: Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. Journal of Gastrointestinal Surgery 2009, 13:2050-8.
40. Simons JP, Ng SC, McDade TP, et al.: Progress for resectable cancer?: a population-based assessment of US practices. Cancer 2010, 116:1681-90.
41. Russ AJ, Weber SM, Rettammel RJ, et al.: Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Annals of Surgical Oncology 2010, 17:371-6.
42. Chu CK, Mazo AE, Goodman M, et al.: Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Annals of Surgical Oncology 2010, 17:502-13.
43. Stratford JK, Bentrem DJ, Anderson JM, et al.: A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Medicine 2010, 7(7): e1000307. This article describes how the gene expression profiles of primary tumors from patients with localized compared to metastatic disease were analyzed, leading to the identification of a six-gene signature associated with metastatic disease. Their results assist in the staging of pancreatic cancer patients and help to select patients whose tumor biology may benefit most from neoadjuvant therapy.
44. Hidalgo M: Medical progress: pancreatic cancer. New England Journal of Medicine 2010, 362:1065-17. This article is an excellent review of the epidemiology of pancreatic cancer, and describes the most recent management and treatment findings.
45. Neoptolemos JP, Stocken DD, Bassi C, et al.: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-81. Although gemcitabine is a superior treatment for advanced pancreatic cancer, conflicting evidence exists regarding its merits over 5-fluoruracil as adjuvant therapy in postsurgical patients. The European Study Group for Pancreatic Cancer (ESPAC)-3 compared the chemotherapeutic agents fluorouracil and gemcitabine in resected pancreatic cancer patients, evaluating overall survival, toxicity, progression-free survival, and quality of life. They found no significant differences in either progression-free survival or global quality-of-life scores between the treatment groups, but toxicity was greater in patients treated with 5-fluoruracil.
46. Berlin J, Benson AB, 3rd: Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. Nature Reviews Clinical Oncology 2010, 7:135-7.
47. O'Reilly EM: Refinement of adjuvant therapy for pancreatic cancer. JAMA 2010, 304:1124-5.
48. Stathis A, Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology 2010, 7:163-72.
49. Wong HH, Lemoine NR, Wong HH, et al.: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature Reviews Gastroenterology & Hepatology 2009, 6:412-22.
50. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, et al.: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treatment Reviews 2009, 35:335-9.